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Abstract
Background: Plasminogen activation is a ubiquitous source of fibrinolytic and proteolytic activity. Besides its role in
prevention of thrombosis, plasminogen is involved in inflammatory reactions in the central nervous system.
Plasminogen has been detected in the cerebrospinal fluid (CSF) of patients with inflammatory diseases; however, its
origin remains controversial, as the bloodCSF barrier may restrict its diffusion from blood.
Methods: We investigated the origin of plasminogen in CSF using Alexa Fluor 488labelled rat plasminogen
injected into rats with systemic inflammation and bloodCSF barrier dysfunction provoked by lipopolysaccharide
(LPS). Near-infrared fluorescence imaging and immunohistochemistry fluorescence microscopy were used to identify
plasminogen in brain structures, its concentration and functionality were determined by Western blotting and a
chromogenic substrate assay, respectively. In parallel, plasminogen was investigated in CSF from patients with
Guillain-Barré syndrome (n = 15), multiple sclerosis (n = 19) and noninflammatory neurological diseases (n = 8).
Results: Endogenous rat plasminogen was detected in higher amounts in the CSF and urine of LPS-treated animals
as compared to controls. In LPS-primed rats, circulating Alexa Fluor 488labelled rat plasminogen was abundantly
localized in the choroid plexus, CSF and urine. Plasminogen in human CSF was higher in Guillain-Barré syndrome
(median = 1.28 ng/μl (interquartile range (IQR) = 0.66 to 1.59)) as compared to multiple sclerosis (median = 0.3 ng/μl
(IQR = 0.16 to 0.61)) and to noninflammatory neurological diseases (median = 0.27 ng/μl (IQR = 0.18 to 0.35)).
Conclusions: Our findings demonstrate that plasminogen is transported from circulating blood into the CSF of rats
via the choroid plexus during inflammation. Our data suggest that a similar mechanism may explain the high CSF
concentrations of plasminogen detected in patients with inflammation-derived CSF barrier impairment.
Keywords: Bloodcerebrospinal fluid barrier, Inflammation, LPS, Plasminogen
Introduction
Vessel wall fibrinolytic activity and pericellular proteoly-
sis in tissues requires plasminogen binding and trans-
formation into plasmin at the surface of fibrin, cells or
the extracellular matrix by either the tissue-type plas-
minogen activator (tPA) or the urokinase-type plasmino-
gen activator (uPA) [1]. The binding of plasminogen to
cells or fibrin is a lysine-dependent mechanism that can
be inhibited by lysine analogues such as tranexamic acid
(TXA). In the vasculature, plasmin formation results in
blood clot dissolution [2], whereas in tissues, plasmin is
responsible for pericellular proteolysis accompanying
cell migration, angiogenesis, wound healing, tissue re-
modelling and inflammation [3-5]. Pericellular proteoly-
sis in the central nervous system (CNS) is involved in
development, regeneration of nervous tissues, neuronal
and synaptic plasticity and the inflammatory response
[6-9]. In humans, plasminogen deficiency is associated
with neural disorders including congenital hydroceph-
alus, periventricular nodular heterotopias and Dandy-Walker
malformation [10]. Trace amounts of plasminogen have been
reported in normal human cerebrospinal fluid (CSF), whereas
raised concentrations have been detected in patients with
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meningitis [11], subarachnoid haemorrhage [12] and multiple
sclerosis [13]. However, the question has not been settled as
to whether plasminogen in CSF originates from circulating
blood or is expressed in the CNS, as suggested by the pres-
ence of mRNA in mouse brain [14,15] or by its synthesis by
rat microglial cells in culture [16].
The CNS is protected from the bloodstream by the
bloodbrain barrier (BBB) and the bloodCSF barrier
[17,18]. The BBB is the barrier separating the brain
interstitial fluid compartment from the general circula-
tion (endothelial tight junctions, basal lamina of endo-
thelial cells and astrocyte pedicles). It selectively limits
penetration of a variety of noxious substances and sup-
plies the brain with nutrients. The bloodCSF barrier
separates the CSF compartment from blood through
choroid plexus epithelial cells, tight junctions, a basal
membrane and the endothelium. It restricts the passage
of harmful substances from the blood into the CSF se-
creted across the choroid plexus epithelial cells into the
brains ventricular system [18]. Because the bloodCSF
barrier is more permeable than the BBB, many plasma
proteins enter the cerebrospinal liquid (through pinocyt-
osis or active transport). An impairment of the bloodCSF
barrier thus leads to an increase in the concentration of
proteins in the CSF.
Because diffusion of plasma proteins into the CNS is a
selective process, we sought to demonstrate that circu-
lating plasminogen may cross the bloodCSF barrier
and can be detected in the CSF. For that purpose, we
studied control rats and rats with lipopolysaccharide
(LPS)-induced systemic inflammation. Our results show
that circulating plasminogen enters the CSF space dur-
ing bloodCSF barrier dysfunction induced by systemic
inflammation, thus suggesting that plasminogen found
in the CSF of patients with inflammatory neurological
disorders originates from circulating blood.
Materials and methods
Reagents and proteins
The enhanced chemiluminescence reagent kit was
obtained from Bio-Rad Laboratories (Hercules, CA,
USA). The chromogenic substrate selective for plasmin
(methylmalonyl)-hydroxyprolylarginine-para-nitroaniline
(CBS0065) was purchased from Stago (Asnières-sur-
Seine, France). Escherichia coli LPS serotype 0111:B4,
trans-4-(aminomethyl)cyclohexane-1-carboxylic acid (or
tranexamic acid, TXA), amiloride and 4,6-diamidino-
2-phenylindole (DAPI) and Evans blue were obtained
from Sigma Chemical Co (St Louis, MO, USA). Alexa
Fluor 488 succinimidyl ester was purchased from Life
Technologies (Carlsbad, CA, USA). Goat anti-collagen
type IV (Col IV) used for immunohistochemical analyses
was obtained from Southern Biotech (Birmingham, AL,
USA), and donkey anti-goat antibody F(ab)2 fragments
linked to tetramethylrhodamine isothiocyanate were
purchased from Jackson ImmunoResearch (West Grove,
PA, USA). Glu-plasminogen, plasmin and peroxidase-
conjugated monoclonal antibody against plasminogen
kringle 1 (CPL15-PO) were prepared and characterized
as described previously [19-21]. A rabbit anti-mouse
plasminogen polyclonal antibody was kindly provided
by HR Lijnen (University of Leuven, Belgium).
Patient sampling
A total of 42 patients with neurological diseases attend-
ing the Neurological Clinic of the Careggi University
Hospital, Florence, Italy, were admitted in this study. In-
formed consent was obtained according to the Declar-
ation of Helsinki. The Careggi University Hospital Review
Board approved the protocol. Diagnoses were based on
clinical, laboratory and magnetic resonance imaging data
according to the International Classification of Diseases,
Tenth Revision, and the Diagnostic and Statistical Man-
ual of Mental Disorders, Fourth Edition–Text Revision
[22]. Patients with Parkinsons disease, brain tumour,
epilepsy and alcohol or other substance dependence
were excluded. All CSF samples were obtained by lum-
bar puncture and were immediately used for routine
laboratory analyses, which included erythrocyte and
leucocyte differential cell counts, total protein concen-
tration, albumin and immunoglobulin G (IgG) levels
and agarose isoelectric focusing for IgG oligoclonal
bands. CSF samples with increased lymphocyte counts
(>5 mm3) or with blood contamination (erythrocyte
concentration >50 cells/mm3) were excluded. The CSF
to serum albumin quotient (Qalb) was calculated and
used to evaluate bloodCSF barrier integrity. Qalb >
0.007 was considered a marker of bloodCSF barrier
dysfunction [23,24]. The remainder of each sample was
stored in aliquots at −80°C for further analysis.
Animal experimental model
Experiments were performed using male Wistar rats
(280 to 350 g) in accordance with the directives of the
Council of the European Communities (86/609/EEC)
and the French Agriculture and Forestry Ministry for
handling animals (decree 87-848).
Purification and labelling of rat plasminogen
To monitor plasminogen uptake by cells and tissues
in vivo in the rat model of inflammation, we used
fluorescence-labelled native plasminogen purified from
rat plasma. Blood was obtained by cardiac puncture of
anaesthetized animals and collected in 0.129 M sodium
citrate. The plasma was separated from blood by centri-
fugation, and plasminogen was isolated by lysine affinity
and sieving chromatography as described previously
[19]. The purified plasminogen had a relative molecular
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weight (Mr = 92,000 Da) similar to that of human plas-
minogen and was labelled with Alexa Fluor 488 dye (A488-
Pg) according to the instructions of the manufacturer.
Rat model of systemic inflammation
Rats were assigned to either LPS treatment (L) or the sa-
line control group (C) (n = 3 rats per group (Figure 1).
Groups L1, L2 and L3 received an intraperitoneal injec-
tion of LPS (1 mg/kg) diluted in saline solution, and
control groups C1, C2 and C3 received only the saline
solution. This dosage of LPS has already been demon-
strated to be able to induce brain inflammation in the
rat [25]. Groups L1 and C1 received no other treatment.
Groups L2 and C2 received a tail vein injection of A488-
Pg (1 mg) 18 hours after LPS or saline administration.
Group L3 received a tail vein injection of 10 mg/kg TXA
30 minutes after LPS administration, followed by a sub-
cutaneous dose of 100 mg/kg TXA. After 18 hours, each
rat received a tail vein injection of A488-Pg (1 mg) pre-
incubated for 15 minutes with 0.1 M TXA, followed by
a subcutaneous injection of 100 mg/kg TXA. Group C3
received identical doses of TXA, but not of A488-Pg.
This dosage schedule of TXA was necessary to ensure
neutralization of lysine-binding sites in both the en-
dogenous and injected plasminogen. At the end of the
scheduled treatments (24 hours), samples were collected
and animals killed for further studies.
Sample collection
The anaesthetized rats were placed in a stereotaxic
frame and secured with ear bars, and a midline incision
in the skin was made up to the head area to permit easy
access to the cisterna magna. The needle, which was
connected to a draw syringe, was inserted horizontally
and centrally into the cisterna magna for CSF collection.
The CSF sample was slowly drawn into the syringe, and
the colour of the CSF was closely observed to avoid any
possible blood contamination. Approximately 100 μl of
CSF was collected from each animal. After a short cen-
trifugation step (3 minutes at 5,000 g, 4°C) all CSF sam-
ples were immediately flash-frozen in liquid nitrogen
and stored at −80°C until use.
Blood was drawn by cardiac puncture using a 1.2 ×
40mm gauge needle syringe containing a 0.1 volume of
0.129 M sodium citrate. Urine was collected by punctur-
ing the bladder. Plasma was separated from blood by cen-
trifugation at 1,500 g for 15 minutes. All the samples were
kept on ice during collection and kept frozen at −80°C
until use.
Evans blue permeability assay
Rats (n = 3 per group) treated with saline (group C1) or
LPS (group L1) alone or supplemented with TXA
(groups C3 and L3) received a tail vein injection of Ev-
ans blue dye (4% in saline) 4 hours before being killed.
After transcardiac perfusion with heparinized saline, the
brains and kidneys were harvested and plunged into cold
saline until fluorescence measurements were performed.
Evans blue dye permeability was monitored by ex vivo
near-infrared fluorescence (NIRF) imaging using the
IVIS 200 imaging system (Caliper Life Sciences, Hopkinton,
MA, USA).
Time
(h) 
LPS challenged puorg
L1                        L2                          L3 
Saline challenged puorg
C1                      C2                        C3 
0. 5 
18 
24 
i.v. & s.c. TXA 
i.v. A488-Pg        i.v. A488-Pg* 
                                              + s.c TXA 
i.v. & s.c. TXA 
i.v. A488-Pg           s.c. TXA 
Sampling of CSF, plasma and urine Sampling of CSF, plasma and urine
Figure 1 Diagram of rat inflammatory model and study design. Rats were separated in six groups (three rats per group). Groups L1, L2 and
L3 were challenged with 1 mg/kg lipopolysaccharide (LPS), and the control groups (C1, C2 and C3) were challenged with saline. Both LPS and
saline were injected intraperitoneally. *Preincubated with tranexamic acid (TXA); i.v., Intravenous injection of TXA (10 mg/kg) or plasminogen
labelled with Alexa Fluor 488 dye (A488-Pg) (1 mg); s.c., Subcutaneous injection of TXA (100 mg/kg).
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Fluorescence microscopy
After the rats were killed, parts of the brains were post-
fixed with 4% paraformaldehyde in 0.1 M phosphate-
buffered saline, pH 7.4, at 4°C for 18 hours, followed by
24 hours in 20% sucrose and then frozen in isopentane.
For immunocytochemistry, cryostat brain sections (8 μm)
were collected on polylysine-coated slides and incubated
overnight with a goat anti-Col IV primary antibody
(1:1,500), which was revealed with donkey anti-goat
antibody F(ab)2 fragments linked to tetramethylrho-
damine isothiocyanate (1:500). The cells were then coun-
terstained with DAPI, mounted with Fluoprep (Dako,
Glostrup, Denmark) and observed under an epifluores-
cence microscope. Images were digitally captured with
a Leica DM6000 microscope-coupled CoolSnap cam-
era (Leica Microsystems, Wetzlar, Germany) and visual-
ized with METAVUE 5.0 software (Molecular Devices,
Sunnyvale, CA, USA). The detection of exogenously ad-
ministered A488-Pg in those samples was also studied.
Detection of functional plasminogen in cerebrospinal
fluid
Transformation of CSF plasminogen into plasmin was
measured using uPA (5 IU/ml) and a plasmin-selective
chromogenic substrate (0.75 mM CBS0065), as previ-
ously described [26]. In this system, the initial velocity of
p-nitroaniline released from CBS0065 is proportional to
the amount of plasmin(ogen). The ability of TXA to im-
pair plasminogen binding to the cell membrane was in-
vestigated as described previously [27].
Western blot analysis
Human CSF samples (7 μg of total protein) and rat CSF,
urine and plasma (diluted 1:50) samples (10 μl) were
electrophoresed in 8% SDS-PAGE gel under nonreduc-
ing conditions. Proteins were transferred onto a polyvi-
nylidene fluoride membrane, and plasminogen was
revealed using a monoclonal antibody directed against
human plasminogen (CPL15-PO, human CSF samples)
or a rabbit anti-mouse plasminogen polyclonal antibody
(rat samples). The amount of plasminogen was expressed
as the number of pixels directly detected using Image-
Quant TL 7.0 image analysis software with the Image-
Quant LAS 4000 imaging system (GE Healthcare Life
Sciences, Pittsburgh, PA, USA) and expressed as nano-
grams per microlitre by reference to a known amount of
plasminogen (15 ng, 10 μl) electrophoresed under similar
conditions. In rat samples, the amount of plasminogen
was expressed as the number of pixels directly detected
using the image analysis software.
Statistical analysis
Data are representative of at least three independent ex-
periments and are expressed as median (25th to 75th
interquartile range (IQR)). The MannWhitney U test
was used to compare values obtained in treated versus
control rats. For human experiments, one-way analysis
of variance (ANOVA) was performed to compare the pa-
tient groups. Bonferronis multiple-comparisons posttest
was run for the pairwise comparison of groups. Statis-
tical significance was set at P < 0.05. A specific statistical
package for exact nonparametric inference (Stata Statis-
tical Software release 9 (2005); StataCorp, College Sta-
tion, TX, USA) was used.
Results
Lipopolysaccharide-induced increase in plasminogen in
rat cerebrospinal fluid
Endogenous plasminogen was detected by Western im-
munoblotting in plasma, CSF and urine of both LPS- and
saline-treated control rats (groups L1 and C1, respectively)
(Figure 2A). The LPS injection produced no significant
variation in the amount of circulating plasminogen as
compared to controls (0.1-fold increase in injected versus
control rats) (Figure 2B). In contrast, we detected higher
plasminogen levels in CSF and urine from LPS-treated
rats (fourfold increase in CSF, P = 0.0002; twofold increase
in urine, P = 0.0071 (both by MannWhitney U test))
(Figure 2B). Rat CSF plasminogen was efficiently trans-
formed into plasmin; its active concentration appeared
to be directly related to the amount of plasminogen
detected in CSF samples by Western immunoblotting
(P = 0.0045, MannWhitney U test) (Figure 2C).
Lipopolysaccharide-induced increase in barrier
permeability
The aforementioned data suggest that vascular perme-
ability was modified following the LPS injection. This
hypothesis was investigated by testing permeability to
Evans blue dye. Ex vivo fluorescent and NIRF images
showed higher brain fluorescence in the LPS-treated rats
(group L) as compared to controls (group C), indicating
an increase in barrier permeability to the dye due to
bloodCSF barrier impairment (Figure 3A). Modifica-
tions in the glomerular filtration barrier were also de-
tected with the Evans blue test (Figure 3B). Higher
kidney fluorescence was observed in LPS-treated rats
(group L) as compared to controls (group C). The ad-
ministration of TXA (groups C3 and L3) was without ef-
fect on barrier permeability.
In vivo evidence of the circulating origin of plasminogen
in cerebrospinal fluid
To obtain in vivo evidence of the extravasation of plas-
minogen from blood, animals were challenged with ex-
ogenous A488-Pg 18 hours after the LPS (group L2) or
saline injection (group C2). A488-Pg appeared in the
CSF and urine of all LPS-treated rats, indicating that
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blood plasminogen crosses the barrier during its pres-
ence in the circulation (with a half-life of about 2 days)
(Figure 4A) and integrates the CSF exchanged at least
three times daily [28]. Actually, the presence of circulat-
ing A488-Pg was clearly visualized by fluorescence mi-
croscopy only in the choroid plexus of LPS-treated rats
(Figure 4B). Figure 4C is a magnified view of the choroid
plexus showing the presence of A488-Pg and the vessel
wall detected by immunocytochemistry of Col IV. Of
note, A488-Pg is absent in the saline-treated control.
Typically, binding of plasminogen by cells is mediated
by a lysine-dependent mechanism via lysine residues
encompassed in cellular receptors and lysine-binding
sites located in plasminogen kringle domains [1]. To
explore whether the passage of plasminogen through the
bloodCSF barrier implicates a lysine-dependent mech-
anism, we measured cellular uptake of A488-Pg in the
presence of the lysine analogue TXA. Figure 5 shows
that plasminogen remained increased in the CSF of rats
treated with TXA, thus excluding uptake via known
plasminogen receptors harbouring carboxy-terminal ly-
sine residues [1].
To substantiate the relevance of these in vivo rat studies
to human pathology, we investigated the presence of plas-
minogen in the CSF of patients with inflammatory and
noninflammatory disorders. Plasminogen antigen was de-
tected in all CSF human samples (Figure 6). Higher con-
centrations of plasminogen were found in Guillain-Barré
(See figure on previous page.)
Figure 2 Determination of plasminogen in rat plasma, cerebrospinal fluid and urine. Samples were obtained from rats challenged with
saline (group C1) versus rats challenged with lipopolysaccharide (LPS) (group L1) (see flowchart in Figure 1). (A) Representative immunoblot
obtained for plasminogen detection using a rabbit antibody to mouse plasminogen. Electrophoresis of reference rat plasminogen (Pg) in an
equal volume (10 μl) of plasma diluted 1:50, cerebrospinal fluid (CSF) and urine. (B) Box-and-whisker plot of plasminogen in plasma, CSF and urine
after immunoblot and densitometric analyses. Results represent median (25th to 75th interquartile range (IQR)). *P = 0.0002 and §P = 0.0071 in
CSF and urine (MannWhitney U test), respectively. (C) Box-and-whisker plot of measurement of the activation of plasminogen in CSF samples
(chromogenic substrate assay). Results represent median (IQR) of the velocity of plasmin formation. #P = 0.0045 (MannWhitney U test). mOD: milli
optical density.
Figure 3 Blood–cerebrospinal fluid barrier and glomerular barrier permeability to Evans blue dye. Ex vivo fluorescent (F) and near-infrared
fluorescent (NIRF) images of brains and kidneys from rats injected with Evans blue dye 24 hours after lipopolysaccharide (LPS) treatment according
to the outline in Figure 1. The measurement was performed in perfused brains 24 hours after Evans blue dye injection. C1, Saline-challenged rats; L1,
LPS-challenged rats; C3, Saline/tranexamic acid (TXA); L3, LPS/TXA; Neg control, Rat without Evans blue dye; BF, Bright field. (A) Brain NIRF
images. (B) Kidney NIRF images. The high fluorescence intensity observed in LPS-treated rats (L1 and L3) compared to saline-treated rats (C1
and C3) indicates leakage of the bloodcerebrospinal fluid barrier (A) or the glomerular filtration barrier (B). No differences were observed
between saline-treated (C1) and TXA-treated (C3) animals, indicating no effect of TXA on extravasation of Evans blue dye.
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syndrome (GBS) (median = 1.28 ng/μl (25th to 75th inter-
quartile range (IQR) = 0.66 to 1.59), n = 15) as compared to
multiple sclerosis (MS) (median = 0.3 ng/μl (IQR= 0.16 to
0.61), n= 19) and noninflammatory neurological diseases
(NINDs) (median = 0.27 ng/μl (IQR = 0.18 to 0.35), n = 8)
(P < 0.0001, one-way ANOVA). The pairwise comparison
yielded significant differences in GBS versus MS (P < 0.05)
and GBS versus NINDs (P < 0.05), both analysed with
Bonferronis posttest. GBS patients had significantly
higher values of CSF total protein, albumin and IgG, as
well as higher Qalb, whereas MS patients had higher
index values of IgG (QIgG/Qalb) (see Additional file 1:
Table S1).
Discussion
Plasminogen is synthesized mainly by the liver and then
is distributed to tissues via the systemic circulation [29].
The concentration of plasminogen in circulating blood
is relatively high (1.5 to 2 μM) and constant, as plas-
minogen does not behave as an acute phase reactant
such as fibrinogen. Therefore, inflammatory conditions
or the injection of an inflammatory agent such as LPS
do not increase the circulating concentration of plas-
minogen. However, a mechanistic link between inflam-
mation and the bloodCSF barrier dysfunction has been
established [30], which may explain an increased transfer
of plasminogen from circulating blood to CSF. Indeed,
trace amounts of plasminogen have been found in the
CSF of patients with noninflammatory diseases [31,32]. By
using an LPS-induced model of systemic inflammation in
rats, we found that plasminogen is present at significantly
higher concentrations in the CSF of LPS-treated rats as
compared to controls. Accordingly, LPS-treated rats had
increased bloodCSF barrier permeability, as demon-
strated with Evans blue dye. CSF plasminogen is efficiently
transformed into plasmin, thus suggesting that transfer of
plasminogen from circulating blood to the CSF could be a
source for plasmin formation in the nervous system. Fur-
thermore, using A488-Pg, we found that this labelled ex-
ogenous rat plasminogen crosses the bloodCSF barrier.
The half-life of plasminogen in the circulation is about 2
days, whereas the CSF is produced and exchanged by cells
of the choroid plexus at least three times daily [28]. Thus,
circulating A488-Pg could be detected in the CSF and the
Figure 4 In vivo evidence of the circulating origin of plasminogen in cerebrospinal fluid. Samples were obtained from rats injected with
plasminogen labelled with Alexa Fluor 488 dye (A488-Pg). Group L2 rats were challenged with lipopolysaccharide (LPS), and group C2 was
challenged with saline (see flowchart in Figure 1). (A). An equal volume (10 μl) of either plasma diluted 1:50 or of cerebrospinal fluid (CSF) or
urine was electrophoresed, and fluorescence (F) in the gel was directly revealed using ImageQuant TL 7.0 image analysis software (upper panel).
The gel was then transferred onto a polyvinylidene fluoride membrane and detected by Western blotting with a rabbit antibody to mouse
plasminogen (WB, lower panel). Representative samples are shown. (B) Micrograph showing the presence of circulating A488-Pg (indicated by
arrows) in the choroid plexus of an LPS-treated rats detected by direct fluorescence microscopy. 4,6-diamidino-2-phenylindole (DAPI) staining
(blue) indicates cell nuclei. (C) Magnified images of choroid plexus of saline- and LPS-treated rats showing the presence of circulating A488-Pg
(indicated by yellow arrows) only in the LPS condition, as detected by direct fluorescence microscopy. DAPI staining (blue) indicates cell
nuclei, and collagen type IV (Col IV, red) is used as a vessel marker.
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choroid plexus of LPS-treated rats. These in vivo data sug-
gest that circulating plasminogen enters the CSF at the
choroid plexus. This enormous epithelial/endothelial sur-
face area is potentially available for untoward leakage of
plasma proteins into CSF [33,34]. Because LPS is also
known to induce interference with the integrity of the
glomerular filtration barrier [35], we also investigated the
passage of plasminogen through the renal glomerulus. We
detected modifications in the glomerular filtration barrier
with the Evans blue test and high concentrations of both
endogenous plasminogen and A488-Pg in the urine of
LPS-treated rats as compared to trace amounts found in
control rats.
Binding of plasminogen to carboxy-terminal lysine resi-
dues of membrane receptors is a well-known mechanism
governing its capture and concentration onto the cell sur-
face, where it can be either transformed into plasmin or
internalized [1]. Because these receptors could potentially
be involved in the transfer of plasminogen from blood to
CSF, we tested the possibility that TXA, a lysine analogue,
might prevent plasminogen from entering the CSF.
Occupation of the lysine-binding site of plasminogen
by TXA prevents binding to lysine residues of mem-
brane glycoprotein receptors. However, TXA did not
inhibit A488-Pg transfer through the bloodCSF bar-
rier, thus suggesting that other binding sites might be
involved in plasminogen uptake. For instance, a pep-
tide derived from the plasminogen-binding site domain
1 of M6PIGF2R, peptide fragment 18 to 36, induces
plasminogen internalization [36].
Figure 5 Effect of tranexamic acid on plasminogen transfer
through the blood–cerebrospinal fluid barrier and the renal
glomerulus. Rats with lipopolysaccharide (LPS)-induced systemic
inflammation received an intravenous injection of plasminogen
labelled with Alexa Fluor 488 dye (A488-Pg) alone (group L2) or in
the presence of sustained concentrations of tranexamic acid (TXA)
(group L3) (see flowchart in Figure 1). Plasminogen was detected by
immunoblotting. (A) Representative immunoblot of rat plasminogen
(Pg), plasma diluted 1:50 cerebrospinal fluid (CSF) and urine samples
using a rabbit antibody to mouse plasminogen. Experiments were
performed as indicated in Figure 2 with an equal volume (10 μl) of
each sample. (B) Representative column bars of plasminogen in
plasma, CSF and urine after immunoblot and densitometric analysis.
Figure 6 Quantification of plasminogen in human
cerebrospinal fluid. Cerebrospinal fluid (CSF) samples were
collected from patients with Guillain-Barré syndrome (GBS, n = 15),
multiple sclerosis (MS, n = 19) and noninflammatory neurological
disease (NIND, n = 8). (A) Representative human CSF immunoblot
showing peroxidase-conjugated monoclonal antibody directed
against plasminogen kringle 1 (CPL15-PO). Electrophoresis of human
plasminogen (Pg) (Mr = 92,000 Da), 10 μl of human plasma diluted 1:50
and 7 μg of total protein in CSF. (B) Box-and-whisker plot of human
CSF plasminogen after immunoblot analysis and densitometric analysis.
Results represent median (interquartile range) (P < 0.0001, one-way
analysis of variance). *P < 0.05 for GBS versus MS and §P < 0.05 for GBS
versus NIND (Bonferronis multiple-comparisons posttest).
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Collectively, these findings demonstrate that, during
inflammation, plasminogen is transported from circulat-
ing blood into the CSF of rats via the choroid plexus.
Interestingly, the high plasminogen CSF content de-
tected in LPS-treated versus control rats parallels the
significantly higher concentration of plasminogen found
in the CSF of patients with bloodCSF barrier dysfunction
determined on the basis of a high Qalb. In agreement with
previously published data [31,32], we found that plas-
minogen is present in trace amounts in noninflammatory
CSF samples. However, we found significantly higher con-
centrations in the CSF of patients with bloodCSF barrier
dysfunction. Our present data are in accord with our pre-
vious demonstration of the presence of apolipoprotein(a),
a glycoprotein homologous to plasminogen in the CSF of
patients with bloodCSF barrier dysfunction [37].
Although there are limitations to translating results
obtained in experimental animals to human diseases,
our data are suggestive of a similar mechanism for plas-
minogen transfer from blood to CSF and may be of rele-
vance to patients with inflammation-derived CSF barrier
impairment.
Conclusions
We have demonstrated that plasminogen is increased in
the CSF of patients with a dysfunctional bloodCSF barrier.
We have reproduced, in an in vivo rat model of systemic
inflammation, similar modifications of barrier function, and
we also have demonstrated that plasminogen from circulat-
ing blood enters the CSF space. Altogether our data strongly
suggest that the increase in CSF plasminogen concentrations
detected in patients obeys a mechanism by which circulating
plasminogen crosses the altered bloodCSF barrier.
Additional file
Additional file 1: Table S1. Study groups and CSF biochemical
parameters.
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